A clinical trial, while not meeting primary and secondary endpoints, might suggests promise for filgotinib in subgroups of pSS patients with biomarker guidance, stabilizing salivary and tear production and reducing IFN activity (Price et al., 2022). The gene discussed is IFNA1; the disease is peeling skin syndrome.